RT Journal Article
SR Electronic
T1 Estimating the burden of scleroderma disease in Spain.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2236
OP 2242
VO 34
IS 11
A1 Ana Villaverde-Hueso
A1 Elena Sánchez-Valle
A1 Elena Alvarez
A1 Consuelo Morant
A1 Patricia E Carreira
A1 María Concepción Martín-Arribas
A1 Ricard Gènova
A1 Alejandro Ramírez-González
A1 Manuel Posada de la Paz
YR 2007
UL http://www.jrheum.org/content/34/11/2236.abstract
AB OBJECTIVE: Scleroderma (systemic sclerosis) is a rare disease that results in great suffering. We estimated the burden of disease posed by scleroderma and its relative importance in the health of the Spanish population. METHODS: We estimated scleroderma-based burden of disease following procedures developed for the Global Burden of Disease study to ensure comparability. RESULTS: Despite its low prevalence, scleroderma generated 1732 disability-adjusted life-years (DALY) in Spain in 2001, comprising 562 (32%) years of life lost and 1170 (68%) years lived with disability. Most scleroderma-related DALY (73%) occurred in the population aged 15-54 years. Estimated DALY accounted for 0.59% of other musculoskeletal disorder-related DALY in the European A subregion (countries with low mortality rate in both adults and children in the World Health Organization classification), a significant value in the overall burden of disease. CONCLUSION: The burden of scleroderma in Spain was high, with disability being the major contributing factor. Burden of disease is an important measure in rare diseases, and may be an important indicator to be considered as a health unit in developed countries.